Angle posted a loss before tax of 15.0 million pounds for the year ended 31 December 2024 compared to a loss of 21.6 million pounds, prior year. Loss per share was 4.82 pence compared to a loss of 7.73 pence. Revenue increased to 2.86 million pounds compared to 2.19 million pounds.
ANGLE Chief Executive, Andrew Newland, said: "We entered 2025 with our large pharma contracts either successfully completed or progressing well and are confident that these have the potential to lead to larger scale opportunities."
The company is funded into first quarter, 2026.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.